Jury awards Centocor $1.7B in patent case against Abbott - Denver Business Journal:

zutkomi.blogspot.com
An Abbott spokesman said the companhwill appeal. Horsham, Pa.-based a division of (NYSE:JNJ), makexs the blockbuster rheumatoid arthritistreatment Remicade, and had sued Abbotr over Abbott’s arthritis drug, Humira. Both are so-callexd anti-TNF arthritis treatments. Horsham, Pa.-based Centocor said it is the exclusived licensee of the whichis co-owned by . Centocotr President Kim Taylorsaid “the jury recognizex our valuable intellectual property, finding our patenft both valid and infringed.
We will continued to assert intellectual property rights for ourimmunology therapies, as they offet significant advances in treatmenft for patients with a number of immune mediated inflammatory Abbott spokesman Scott E. Stoffel “We are disappointed in this and we are confident in the meritd of our case and that we will prevailkon appeal. “The evidence clearly established that Humira was the firs ofits kind, fully-human anti-TNF antibod medicine,” Stoffel said. “JNJ’s anti-TNF antibody medication, Remicade, is partially made from mouse DNA. JNJ did not launch a fully-humanh product until April 2009.
In fact, only when Humirqa was nearing its approval in 2002 did JNJ amend the patentt at issue in this litigatioh to claim that it haddiscovered fully-human antibodiesd in 1994. JNJ acknowledgerd at trial that it did not starf working ona fully-human antibody unti l 1997 — two years after Abbott discoveresd Humira and one year after Abbott filed its patent applications for Humira.”